Karyopharm Therapeutics (KPTI) Change in Receivables (2019 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly Change in Receivables came in at -$5.7 million in Q4 2025, down 463.14% YoY from $1.6 million in Q4 2024, and down 440.19% on a QoQ basis from -$1.1 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Change in Receivables (2019 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 7 years of Change in Receivables data on file, last reported at -$5.7 million in Q4 2025.
- Quarterly Change in Receivables fell 463.14% year-over-year to -$5.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.6 million (down 220.61% YoY) and the FY2025 annual result came in at -$4.6 million, down 220.61% from the prior year.
- Change in Receivables eased to -$5.7 million in Q4 2025, from -$1.1 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $6.9 million in Q2 2024 to a low of -$11.9 million in Q1 2023.
- A 5-year average of -$310400.0 and a median of $89500.0 in 2021 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables surged 358.61% — and 2023, when it plunged 8219.26%.
- Tracing KPTI's Change in Receivables over 5 years: stood at $3.7 million in 2021, then plunged by 96.4% to $135000.0 in 2022, then sank by 8219.26% to -$11.0 million in 2023, then jumped by 90.77% to -$1.0 million in 2024, then slumped by 463.14% to -$5.7 million in 2025.
- The last three Change in Receivables figures came in at -$5.7 million (Q4 2025), -$1.1 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.70 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | -1.06 Mn |
| Sep 30, 2025 | -1.06 Mn |
| Jun 30, 2025 | -2.31 Mn |
| Jun 30, 2025 | -2.31 Mn |
| Mar 31, 2025 | 4.48 Mn |
| Mar 31, 2025 | 4.48 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Sep 30, 2024 | -6.22 Mn |
| Sep 30, 2024 | -6.22 Mn |
| Jun 30, 2024 | 6.91 Mn |
| Jun 30, 2024 | 6.91 Mn |
| Mar 31, 2024 | 4.12 Mn |
| Mar 31, 2024 | 4.12 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Sep 30, 2023 | 5.64 Mn |
| Sep 30, 2023 | 5.64 Mn |